Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration.
D000368:Aged; D003167:Complement Activation / Q000187:drug effects*; D016503:Drug Delivery Systems; D015195:Drug Design; D004345:Drug Industry; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000494:pharmacology*
C545885:POT-4 peptide; D010456:Peptides, Cyclic